Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
University of North Carolina at Chapel Hill · University of North Carolina Health Care · +13 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
789
total citations
- FWCI
- 32.92
- Percentile
- 100%
- References
- 41
Citations per year
Authors
624- JFJames F. HowardCorresponding
University of North Carolina at Chapel Hill, University of North Carolina Health Care
- KUKimiaki Utsugisawa
National Hospital Organization Hanamaki Hospital
- MBMichael Benatar
University of Miami
- HMHiroyuki Murai
International University of Health and Welfare
- RJRichard J. Barohn
University of Kansas Medical Center
Topics & keywords
Topics
Keywords
- Myasthenia gravis
- Eculizumab
- Refractory (planetary science)
- Medicine
- Placebo
- Double blind
- Acetylcholine receptor
- Antibody
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.